Transaction DateRecipientSharesTypePriceValue
22nd February 2021Emma Reeve6,260Exercise of derivative$8.04$50,330.40
22nd February 2021Emma Reeve6,260Open or private sale$37.60$235,373.50
19th February 2021Emma Reeve4,010Open or private sale$37.71$151,217.90
19th February 2021Emma Reeve4,010Exercise of derivative$8.04$32,240.40
18th February 2021Emma Reeve1,100Exercise of derivative$8.04$8,844.00
18th February 2021Emma Reeve1,100Open or private sale$37.58$41,343.06
17th February 2021Emma Reeve410Exercise of derivative$8.04$3,296.40
17th February 2021Group L P Column10,000Open or private sale$36.95$369,503.00
17th February 2021Emma Reeve410Open or private sale$37.56$15,397.84
2nd February 2021Mark A Goldsmith5,000Exercise of derivative$1.12$5,600.00
Constellation Pharmaceuticals
Constellation Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel therapeutics in the field of epigenetics. Its product candidates include CPI-0610, CPI-1205, and CPI-0209.


Ticker: CNST
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1434418
Employees: 106
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $179 M (0%)
Marketable Securities, Current: $341 M (588%)
Assets, Current: $523 M (35%)
Property, Plant and Equipment, Net: $1 M (48%)
Assets: $535 M (33%)
Long-term Debt, Current Maturities: $2 M (0%)
Accounts Payable, Current: $6 M (-22%)
Liabilities, Current: $27 M (19%)
Long-term Debt, Excluding Current Maturities: $28 M (0%)
Other Liabilities, Noncurrent: $716 Th (83%)
Liabilities: $63 M (2%)
Common Stock, Value, Issued: $5 Th (25%)
Common Stock, Shares, Issued: $48 M (13%)
Additional Paid in Capital, Common Stock: $846 M (28%)
Retained Earnings (Accumulated Deficit): $375 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $255 Th (4150%)
Stockholders' Equity (Parent): $472 M (0%)
Liabilities and Equity: $535 M (33%)
Research and Development: $23 M (-47%)
General and Administrative Expenses: $7 M (-45%)
Operating Income/Loss: $30 M (-46%)
Other Income, net: $142 Th (-65%)
Provision for income taxes: $24 Th (-38%)